Trial · NCT02937116
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Experiencing Dose-limiting Toxicities (DLTs) | Up to 28 days in Cycle 1 | |
| Primary | Number of All Study Participants Who Demonstrate a Tumor Response | Through out the study (up to 2 years) | |
| Primary | Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator | Through out the study (up to 2 years) | ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1. |
| Secondary | PFS According to RECIST 1.1 as Assessed by Investigator | Through out the study (up to 2 years) | |
| Secondary | DOR According to RECIST 1.1 as Assessed by Investigator | Through out the study (up to 2 years) | |
| Secondary | TTR According to RECIST 1.1 as Assessed by Investigator | Through out the study (up to 2 years) | |
| Secondary | OS for Participants | Through out the study | |
| Secondary | Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t) | Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29 | |
| Secondary | Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants | Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29 | |
| Secondary | Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants | Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29 | |
| Secondary | The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration | Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29 | |
| Secondary | Volume of Distribution of IBI308 in Plasma After Single Dose Administration | Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29 | |
| Secondary | Clearance of IBI308 in Plasma After Single Dose Administration | Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02937116/registered